Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Acta Diabetol. 2019 Mar;56(3):377-378. doi: 10.1007/s00592-018-1262-4. Epub 2018 Dec 1.
No abstract available

Keywords: Alpha-cell pancreatic function; Anti-PD-1; Anti-PD-L1; Autoimmune diabetes; Beta-cell pancreatic function; Coefficient of variation for glucose; Diabetes mellitus; Exocrine pancreatic function; Flash glucose monitoring; FreeStyle Libre; Fulminant diabetes; Glucose variability; Immune checkpoint inhibitors side effects; Immunotherapy; Labile diabetes; Programmed cell death-1; Programmed death ligand 1.

Publication types

  • Comment

MeSH terms

  • B7-H1 Antigen*
  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 1*
  • Follow-Up Studies
  • Glucose
  • Humans
  • Nivolumab
  • Programmed Cell Death 1 Receptor

Substances

  • B7-H1 Antigen
  • Blood Glucose
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • Glucose